INVESTMENT SECURITIES, RELATED PARY (Tables)

6 Months Ended

Mar. 31, 2022

Investment Securities Related Pary

Schedule of dividend income

Fair Value of Intellectual Property	$	1,500
Prepaid Expenses		74,298
Due from Employee		1,071
Note Receivable		64,400
Accrued Interest Receivable		20,274
Investment Securities		593,357
Convertible Note Receivable		10,000
Accounts Payable		1,269,041
Notes Payable		500,000
Accrued Expenses Related Parties		89,529
Accrued Expenses		203,037
Enterprise Value		2,826,507
Less: Total Debt		(2,061,607	)
Portion of Enterprise Value Attributable to Shareholders		764,900
Fair Value  Per Share	$	0.0167

Schedule of comprehensive income

470,588 Common Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter   ended March 31,2022
$	5,741	$	7,858	$	2,118	$	0

725,000 Series M Preferred of Zander Therapeutics, Inc.
	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter  ended March 31, 2022
$	13,124	$	12,109	$	(1,104	)	$	0